ProPhase Labs, Inc. (PRPH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.15. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is PRPH = $14 (+9214.7% upside).
Valuation: PRPH trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).
Financials: revenue is $7M, -31.1%/yr average growth. Net income is $53M (loss), growing at -71.5%/yr. Net profit margin is -788.2% (negative). Gross margin is -2.2% (-43.7 pp trend).
Balance sheet: total debt is $25M against $7M equity (Debt-to-Equity (D/E) ratio 3.34, leveraged). Current ratio is 0.95 (tight liquidity). Debt-to-assets is 38.9%. Total assets: $63M.
Analyst outlook: 1 / 2 analysts rate PRPH as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 50/100 (Partial), Health 0/100 (Fail), Moat 0/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
